Editing Leukemia (section)

===T-cell prolymphocytic===
{{Further|T-cell prolymphocytic leukemia#Treatment}}

Most people with T-cell prolymphocytic leukemia, a rare and aggressive leukemia with a median survival of less than one year, require immediate treatment.<ref name="pmid11535503">{{cite journal | vauthors = Dearden CE, Matutes E, Cazin B, Tjønnfjord GE, Parreira A, Nomdedeu B, Leoni P, Clark FJ, Radia D, Rassam SM, Roques T, Ketterer N, Brito-Babapulle V, Dyer MJ, Catovsky D | title = High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H | journal = Blood | volume = 98 | issue = 6 | pages = 1721–6 | date = September 2001 | pmid = 11535503 | doi = 10.1182/blood.V98.6.1721 | s2cid = 26664911 | doi-access = free }}</ref>

T-cell prolymphocytic leukemia is difficult to treat, and it does not respond to most available chemotherapeutic drugs.<ref name="pmid11535503" /> Many different treatments have been attempted, with limited success in certain people: [[purine analogues]] (pentostatin, fludarabine, cladribine), [[chlorambucil]], and various forms of combination chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone [[CHOP (chemotherapy)|CHOP]], cyclophosphamide, vincristine, prednisone [COP], vincristine, doxorubicin, prednisone, etoposide, cyclophosphamide, bleomycin [[VAPEC-B]]). [[Alemtuzumab]] (Campath), a [[monoclonal antibody]] that attacks white blood cells, has been used in treatment with greater success than previous options.<ref name="pmid11535503" />

Some people who successfully respond to treatment also undergo [[stem cell transplantation]] to consolidate the response.<ref name="pmid11535503" />